MED: financial statements from SEC — TradeAlmanac

MED

MEDIFAST INC: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	76m	89m	106m	116m	140m	169m
Cost of revenue	24m	27m	29m	31m	34m	45m
Gross profit	52m	62m	77m	84m	106m	123m
Selling, general and administrative	55m	66m	78m	86m	104m	131m
Operating income	−3m	−4m	−1m	−1m	2m	−8m
Pre-tax income	−2m	−3m	3m	526,000	2m	−11m
Income tax	181,000	−396,000	395,000	1m	449,000	−2m
Net income	−2m	−2m	2m	−772,000	1m	−8m
Earnings per share	−0.19	−0.21	0.23	−0.07	0.10	−0.75
Earnings per share, diluted	−0.19	−0.21	0.22	−0.07	0.10	−0.75
Weighted average shares	11m	11m	11m	11m	11m	11m
Weighted average shares, diluted	11m	11m	11m	11m	11m	11m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	72m	89m	100m	102m	92m	91m	115m	108m
Short-term investments	97m	78m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	260,000	3m
Depreciation and amortisation	3m	3m
Share-based compensation	2m	2m
Capital expenditure	1m	2m
Investing cash flow	−17m	−2m
Dividends paid	87,000

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)